UCB bets $2 billion on Candid's T cell engager ambitions

Kyle LaHucik / endpoints - Ken Song has done it again. The biopharma veteran's all-out effort to prove T cell engagers' potential in autoimmune diseases is getting picked up by one of Europe’s oldest pharma companies. UCB is paying $2 ...

AI Summary: UCB has struck a roughly $2 billion deal to acquire Candid, betting heavily on Candid’s T‑cell engager platform to reset immune‑based oncology programs. The acquisition boosts UCB’s immuno‑oncology pipeline and signals intensified competition in T‑cell engager development, with investors and researchers watching closely to see how science translates into clinical wins.

---

Warning: Undefined variable $thumbnail in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 61

Related Stories

---

Warning: Undefined variable $top_stories in /home3/thegood9/public_html/website_70aad9ea/cluster.php on line 128

Merck to acquire Terns Therapeutics for $6.7B / 2 months

Bristol Myers and Hengrui strike up to $15.2B global oncology pact / 16 days

Gilead exercises options to accelerate oncology pipeline expansion / 7 wks

Novartis pays $2B for Synnovation’s next‑gen PI3Kα inhibitor / 2 months

Teclistamab outperforms standard regimens in earlier-line relapsed myeloma / 47 hrs

Common asthma drug may overcome immunotherapy resistance in cancers / 11 days

Retifanlimab plus chemotherapy extends survival in advanced squamous anal cancer / 13 days